Research and Markets has announced the addition of the "Cat Allergy - Pipeline Review, H2 2016" report to their offering.
Cat Allergy pipeline therapeutics constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. Our latest report Cat Allergy - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Cat Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Cat Allergy Cat allergy is an allergic reaction to one or more allergens produced by cats. Symptoms include sneezing, runny or stuffy nose, facial pain (from nasal congestion), coughing, chest tightness, shortness of breath and wheezing, watery, red or itchy eyes and skin rash or hives. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 2 and 2 respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Cat Allergy and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/b43n5c/cat_allergy
View source version on businesswire.com: http://www.businesswire.com/news/home/20160928005751/en/Business Wire
Last updated on: 28/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.